Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Knudsen

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Frontiers in Bioscience (Landmark Edition)|May 31, 2011
Tissue factor and factor VIIa cross-species compatibilityTom Knudsen, Ole Hvilsted Olsen, Lars Christian Petersen
Plant Disease|March 13, 2019
A Cerospora Leaf Spot Model for Sugar Beet: In Practice by an IndustryCarol E Windels, H Arthur Lamey, Dave Hilde, et al.
Methods in Molecular Biology (Clifton, N.J.)|June 7, 2012
Mouse embryonic stem cell adherent cell differentiation and cytotoxicity assayMarianne Barrier, Kelly Chandler, Susan Jeffay, et al.
Clinical Pharmacology and Therapeutics|January 4, 2024
Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With InhibitorsAlan Faraj, Joakim Nyberg, Grant E Blouse, et al.
American Journal of Veterinary Research|August 2, 2011
Development of a flow cytometric assay for detection of coated platelets in dogs and evaluation of binding of coated platelets to recombinant human coagulation factor VIIaTom Knudsen, Marianne Kjalke, Mikael Tranholm, et al.
Blood Advances|November 22, 2018
Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout miceRikke Stagaard, Carsten Dan Ley, Kasper Almholt, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 3, 2022
Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drugAlan Faraj, Tom Knudsen, Shraddha Desai, et al.
Advances in Therapy|June 21, 2023
Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B PatientsAlan Faraj, Natacha Le Moan, Eduard Gorina, et al.
Journal of Pharmaceutical Sciences|June 30, 2024
Model-Based Interspecies Scaling for Predicting Human Pharmacokinetics of CB 4332, a Complement Factor I ProteinRami Ayoun Alsoud, Natacha Le Moan, Lars Holten-Andersen, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 12, 2023
Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategyAlan Faraj, Rob C van Wijk, Linda Neuman, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Frontiers in Bioscience (Landmark Edition)|May 31, 2011
Tissue factor and factor VIIa cross-species compatibilityTom Knudsen, Ole Hvilsted Olsen, Lars Christian Petersen
Plant Disease|March 13, 2019
A Cerospora Leaf Spot Model for Sugar Beet: In Practice by an IndustryCarol E Windels, H Arthur Lamey, Dave Hilde, et al.
Methods in Molecular Biology (Clifton, N.J.)|June 7, 2012
Mouse embryonic stem cell adherent cell differentiation and cytotoxicity assayMarianne Barrier, Kelly Chandler, Susan Jeffay, et al.
Clinical Pharmacology and Therapeutics|January 4, 2024
Subcutaneous Marzeptacog Alfa (Activated) for On-Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With InhibitorsAlan Faraj, Joakim Nyberg, Grant E Blouse, et al.
American Journal of Veterinary Research|August 2, 2011
Development of a flow cytometric assay for detection of coated platelets in dogs and evaluation of binding of coated platelets to recombinant human coagulation factor VIIaTom Knudsen, Marianne Kjalke, Mikael Tranholm, et al.
Blood Advances|November 22, 2018
Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout miceRikke Stagaard, Carsten Dan Ley, Kasper Almholt, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 3, 2022
Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drugAlan Faraj, Tom Knudsen, Shraddha Desai, et al.
Advances in Therapy|June 21, 2023
Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B PatientsAlan Faraj, Natacha Le Moan, Eduard Gorina, et al.
Journal of Pharmaceutical Sciences|June 30, 2024
Model-Based Interspecies Scaling for Predicting Human Pharmacokinetics of CB 4332, a Complement Factor I ProteinRami Ayoun Alsoud, Natacha Le Moan, Lars Holten-Andersen, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 12, 2023
Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategyAlan Faraj, Rob C van Wijk, Linda Neuman, et al.
Pageof 2